Search | Clinical Trials Finder

Conditions: Hemorrhagic Shock
Interventions: Glutamine, Ringer's Lactate, Placebo (for Glutamine); Drug
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 21 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Kansas City, Missouri

Conditions: Hemorrhagic Shock
Interventions: Whole blood; Biological
Lead sponsor: Jason Sperry; Other
Eligibility: 18 Years to 89 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Shock,Hemorrhagic
Interventions: Valproic Acid, Isotonic saline solution; Drug
Lead sponsor: Dr. Hasan Alam; Other
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging; Procedure · Biological · Drug
Lead sponsor: Naresh Bumma; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Dengue
Interventions: rDEN3/4delta30(ME), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Traumatic Brain Injury, Hemorrhagic Shock, Trauma
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Trauma Injury
Interventions: Prothrombin Complex Concentrate, Human, Placebo; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Occult Bleeding, Hemorrhage
Interventions: Detection of Occult Hemorrhage in Trauma Patients; Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
Interventions: Pathogen Reduced Cryoprecipitated Fibrinogen Complex; Biological
Lead sponsor: Cerus Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Aurora, Colorado • Miami, Florida • Baltimore, Maryland + 1 more

Conditions: Cytokine Release Syndrome, Neoplasms, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Multiple Myeloma, Lymphoma Mantle-cell, Immunotherapy, Cell and Tissue-Based Therapy, Cytokines, Monitoring Physiologic, Immune Monitoring, Wearable Electronic Devices, Thermometry, Body Temperature, Antibodies Bispecific, Receptors Chimeric Antigen
Interventions: TempTraq, VitalTraq; Device
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions: Siltuximab, Teclistamab(FDA-approved); Drug
Lead sponsor: Jack Khouri, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Trauma, Hemorrhage
Interventions: Cold Stored Platelets (CSP), Standard Care; Biological
Lead sponsor: Jason Sperry; Other
Eligibility: 15 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Jackson, Mississippi + 1 more

Conditions: Hemorrhagic Shock, Traumatic Brain Injury
Interventions: hypertonic saline; Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Shock, Hemorrhagic, Injury Penetrating, Hemorrhage
Interventions: XSTAT, Standard of Care; Device · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 15 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hemorrhagic Shock, Acute Blood Loss Anemia, Traumatic Brain Injury
Interventions: Routine labs; Combination Product
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Hemorrhagic Shock
Interventions: Near-Infrared Diffuse Optical Spectroscopy; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Irvine, California

Conditions: Shock,Hemorrhagic, Trauma
Interventions: Valproic Acid, Isotonic saline solution; Drug
Lead sponsor: Dr. Hasan Alam; Other
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Boston, Massachusetts • Ann Arbor, Michigan

Conditions: Body Response to Trauma
Interventions: Phlebotomy; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 98 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Dengue
Interventions: TetraVax-DV Vaccine-Admixture 1, TetraVax-DV Vaccine-Admixture 2, TetraVax-DV Vaccine-Admixture 3, TetraVax-DV Vaccine-Admixture 4, Placebo, TetraVax-DV Vaccine-Admixture 5; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Burlington, Vermont

Conditions: Multiple Myeloma
Interventions: Teclistamab, Talquetamab, Tocilizumab, Oral Dexamethasone; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 17
States / cities: Tucson, Arizona • Denver, Colorado • Newark, Delaware + 12 more

Conditions: Hemorrhagic Shock, Traumatic Injury
Interventions: low titer whole blood, Standard Care; Biological
Lead sponsor: Jason Sperry; Other
Eligibility: 18 Years to 89 Years
Enrollment: 1,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Birmingham, Alabama • Louisville, Kentucky • Jackson, Mississippi + 7 more

Conditions: Dengue Fever
Interventions: rDEN3delta30/31-7164; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Trauma, Hemorrhagic Shock
Interventions: Type AB plasma, Crystalloid fluid (standard of care for resuscitation); Biological · Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)
Interventions: Linvoseltamab, Tocilizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Los Angeles, California • Baton Rouge, Louisiana • Tacoma, Washington

Search by objective public record fields.

Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy

Pragmatic Prehospital Group O Whole Blood Early Resuscitation Trial

A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1)

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults

The Use of Tissue Oxygen Monitoring in Critically Injured Patients

Prehospital Kcentra for Hemorrhagic Shock

Trauma Study: Early Warning of Progression Toward Hemodynamic Deterioration After Trauma

Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Cold Stored Platelet in Hemorrhagic Shock

Hypertonic Modulation of Inflammation Following Injury

Feasibility of Evaluating XSTAT Use in the Prehospital Setting

Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients

Development of an Algorithm for Prediction of Onset of Hemodynamic Instability in Humans

A Study to Evaluate the Safety and Tolerability of Valproic Acid in Trauma Patients(Part 2)

Vasopressin Deficiency in Hemorrhagic Shock

Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Type O Whole Blood and Assessment of Age During Prehospital Resuscitation Trial

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults

Control of Major Bleeding After Trauma Study

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)